Evidence map›Paper›PMID 40891522›Full record

ArticleThe Cochrane database of systematic reviews2025

Bile acids for metabolic dysfunction-associated steatotic liver disease in adults.

Rehab E Ashmawy, Oleg Blyuss, Dimitrinka Nikolova, Chavdar S Pavlov, Christian Gluud, Paola J Andrenacci

Abstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in The Cochrane database of systematic reviews, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Rehab E AshmawyFaculty of Medicine, Helwan University, Cairo, Egypt.ORCID 0000-0003-1613-4452
Oleg BlyussWolfson Institute of Population Health, Queen Mary University of London, London, UK.
Dimitrinka NikolovaCochrane Hepato-Biliary Group, Copenhagen Trial Unit, Centre for Clinical Intervention Research, The Capital Region, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
Chavdar S PavlovCochrane Hepato-Biliary Group, Copenhagen Trial Unit, Centre for Clinical Intervention Research, The Capital Region, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
Christian GluudCochrane Hepato-Biliary Group, Copenhagen Trial Unit, Centre for Clinical Intervention Research, The Capital Region, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
Paola J AndrenacciEditorial Team, Cochrane Hepato-Biliary Group, Wheelwright, Argentina.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThis is a protocol for a Cochrane Review (intervention). The objectives are as follows: To evaluate the benefits and harms of oral bile acid-based therapies versus no intervention or placebo, or versus a different bile acid-based therapy, at any dose or regimen, in adults diagnosed with metabolic dysfunction-associated steatotic liver disease (MASLD).

Indexed as

Bile Acids and SaltsFatty LiverAdultChenodeoxycholic AcidHumansRandomized Controlled Trials as TopicUrsodeoxycholic AcidBile Acids and SaltsChenodeoxycholic AcidUrsodeoxycholic Acid

Identifiers

PMID40891522
PMCPMC12403225

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.